Molecular and cellular composition changes after neoadjuvant letrozole and palbociclib in early luminal breast cancer.

Fiche publication

Date publication

janvier 2026

Journal

Cell reports. Medicine

Auteurs

Membres identifiés du Cancéropôle Est :
Dr DESMOULINS Isabelle

Tous les auteurs :
Cottu P, Kieffer Y, Lemonnier J, D'hondt V, Duhoux FP, Callens C, Gentien D, Reyes C, Boulai A, Desmoulins I, Mouret-Reynier MA, Levy C, Heudel PE, Dalenc F, Grenier J, Fuhrmann L, Baulande S, Delaloge S, Mechta-Grigoriou F, Vincent-Salomon A

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/41519129

Résumé

The NeoPAL trial compares neoadjuvant letrozole-palbociclib (LP) with chemotherapy (CT) in 103 patients with high-risk, early luminal breast cancer. At surgery, the NanoString BC360 proliferation score and Ki67 expression are reduced in both arms, together with upregulation of immune-related signatures. Overall, there is very little difference in the changes observed with LP as compared to CT, even in signatures related to response to estrogen and CDK4/6 manipulation. Deconvolution of bulk RNA sequencing (RNA-seq) data reveals high content at baseline in cancer cells, immunosuppressive cancer-associated fibroblasts, FOXP3+ CD4 regulatory T lymphocytes, and TREM2+ macrophages. In contrast, myoepithelial cells, normal-like fibroblasts, FOLR2+ macrophages, and SELL+ CD4 T lymphocytes accumulate after treatment in both arms. A low ROR score is observed at surgery in 63.3% and 43.5% of patients in the LP and CT arms, respectively. No 3-year breast cancer-specific survival events are observed in these patients. These data provide a rationale for CT-sparing trials in this setting.